-
and its potential as a therapeutic target. Your work will include: Developing cell-based bioluminescent and fluorescent biosensor assays to detect GPCR signalling events in different cellular models
-
for identifying drug repurposing candidates. You will contribute to different stages of the research project. Your work will include: Developing and using human in vitro models derived from patient and control
-
is the Medicines Evaluation Board (MEB) in Utrecht, the Netherlands. You will be employed by the MEB and embedded in the POLARIS consortium. You will be supervised by Dr Marjon Pasmooij and work
-
will contribute to the development and evaluation of gene therapy approaches for PMLD1. Your work includes: establishing and using isogenic iPSC-derived myelinating organoids as a human in vitro disease
-
candidate, you will contribute to the preclinical development of gene therapy approaches for leukodystrophies. Your work includes: testing the efficacy and safety of AAV gene therapy in VWM and MLD mouse
-
preclinical therapy development. Work collaboratively across different research environments, integrating findings from zebrafish models with data from mammalian models and other experimental systems. As part
-
this project, you will develop new image analysis methodologies for less invasive and non-invasive quantitative brain PET studies using LAFOV PET/CT. You will work on model-independent kinetic analysis methods